Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06129825 · ClinicalTrials.gov registry record
Pharmacologic Induction of Tolerance for Hypoxia & Hypothermia
A clinical trial of Hypoxia and Hypothermia, sponsored by University of Maryland, Baltimore.
- Active
- Registry status
- 50
- Enrollment target
- 1
- Study location
NCT06129825 is a study of Hypoxia and Hypothermia that is active but no longer recruiting, run by University of Maryland, Baltimore. The registered enrollment target is 50 participants, below the 3,116-participant average among 39 other Hypoxia trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06129825, a study of Hypoxia and Hypothermia, is active but no longer recruiting, sponsored by University of Maryland, Baltimore.
- ACTIVE NOT RECRUITING
- Registry status
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
Warfighter Performance Optimization in Extreme Environments remains an area of important and intense investigation, with the following goals: (1) Optimize, sustain and augment medical readiness and physiological/ psychological performance in extreme and hazardous military operational environments and (2) develop joint DoD countermeasures and guidance to sustain performance, assess physiological status, and reduce injury risk in extreme and hazardous operational environments. Successful and safe outcomes in extreme and hazardous operational environments require that warfighters maintain optimum cognitive and exercise performance during physiologic stress. Extreme environmental conditions encountered in such environments include warfighter exposure to hypoxia and hypothermia, alone or in combination. Both hypoxia and hypothermia undermine O2 delivery system homeostasis, imposing dangerous constraints upon warfighter cognitive and exercise capacity. While red blood cells (RBCs) are commonly recognized as O2 transport agents, their function as a key signaling and control node in O2 system delivery homeostasis is newly appreciated. Through O2 content-responsive modulation of RBC energetics, biomechanics, O2 affinity and control of vasoactive effectors in plasma - RBCs coordinate stabilizing responses of the lung, heart, vascular tree and autonomic nervous system - in a fashion that maintains O2 delivery system homeostasis in the setting of either reduced O2 availability (hypobaric hypoxia) or increased O2 demand (hypothermia). Human RBCs demonstrate adaptive responses to exercise, hypoxia and hypothermia - these changes are commonly appreciated as a key element enabling high altitude adaptation. However, under conditions of hypoxia and hypothermia, without prior adaptation, RBC performance is adversely impacted and limits the dynamic range of stress adaptation for O2 delivery homeostasis - therefore limiting warfighter exercise capacity and cognitive performance in extr
Conditions Studied
Interventions
- OTHER Prospective
Study Locations (1)
Maryland
- University of Maryland Baltimore - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2023-12-11 |
| Est. Completion | 2027-12-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06129825
The ClinicalTrials.gov registry entry for NCT06129825 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,116-participant average among 39 other Hypoxia trials with a reported enrollment target (98% lower). The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Hypoxia appearing as the primary indexed condition, and to 1 intervention - of which Prospective is the first listed.
NCT06129825 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT06129825 about?
NCT06129825 is a clinical study titled "Pharmacologic Induction of Tolerance for Hypoxia & Hypothermia". Warfighter Performance Optimization in Extreme Environments remains an area of important and intense investigation, with the following goals: (1) Optimize, sustain and augment medical readiness and physiological/ psychological performance in extreme and hazardous military operational environments an...
What is the current status of trial NCT06129825?
This trial is currently active not recruiting. The enrollment target is 50 participants. The study started on 2023-12-11. Estimated completion is 2027-12-30.
What conditions does trial NCT06129825 study?
This clinical trial studies the following conditions: Hypoxia, Hypothermia, Mountain Sickness.
What interventions are being tested in trial NCT06129825?
The interventions under investigation include: Prospective (OTHER).
Who is sponsoring clinical trial NCT06129825?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06129825 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypoxia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effects of Breathing Training and Nitrate on Exercise at Simulated Altitude
RECRUITING · NA
-
Intravenous Iron Effects on Performance at High Altitude
RECRUITING · Phase 4
-
End-Tidal Oxygen for Intubation in the Emergency Department
RECRUITING · NA
-
Fetal Cerebrovascular Autoregulation in Congenital Heart Disease and Association With Neonatal Neurobehavior
RECRUITING · Phase 2
-
Pulse Oximeter Accuracy in Healthy Humans During Hypoxia
RECRUITING
-
Impact of Early Aging and Menopause on the Vascular Responses to Hypoxia
RECRUITING · Early Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.